Date: 2012-12-10
Type of information: Company acquisition
Acquired company: deCODE Genetics (Iceland)
Acquiring company: Amgen (USA)
Amount: $415 million (€320.8 million)
Terms: Amgen and deCODE Genetics have entered into a definitive agreement under which Amgen will acquire deCODE Genetics , a global leader in human genetics, headquartered in Reykjavik, Iceland . The all-cash transaction values deCODE Genetics at $415 million , subject to customary closing adjustments, and was unanimously approved by the Amgen Board of Directors.
Founded in 1996, deCODE Genetics is a global leader in analyzing and understanding the link between the genome and disease susceptibility. Using its expertise and access to a well-defined population in Iceland , deCODE Genetics has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer. deCODE Genetics' capability in the study of the genetics of human disease will help Amgen to enhance its efforts to identify and validate human disease targets.
This transaction does not require regulatory approval, and is expected to close before the end of 2012.
Details:
Related: Genomics
Human genetics
